CLEARLINK BLOOD RECIPIENT SET
Received Aug 14, 2025 · Event occurred Jul 18, 2025
Report 1416980-2025-04196 · MDR key 22811401
Device
Generic name
Set, Blood Transfusion
Manufacturer
Baxter Healthcare CorporationModel number
FNC1168NCatalog number
FNC1168N
Lot number
24K28T263
Product problems
- Crack
- Fluid/Blood Leak
- Crack
- Fluid/Blood Leak
Patient
NA · Unknown
- No Clinical Signs, Symptoms or Conditions
- No Clinical Signs, Symptoms or Conditions
Narrative
Additional Manufacturer Narrative
SHOULD ADDITIONAL RELEVANT INFORMATION BECOME AVAILABLE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED.
Description of Event or Problem
IT WAS REPORTED THAT TWO (2) BLOOD/SOLUTION ANAESTHESIA/PCA INFUSION SETS WERE FAILING; THE "SIDE ARM" OF THE SET SPONTANEOUSLY CRACKED MIDWAY THROUGH THE CASE AND STARTED LEAKING ONTO THE FLOOR. THIS HAPPENED DURING CLINICAL USE WITH TOTAL INTRAVENOUS ANAESTHESIA (TIVA). THERE WAS NO REPORT OF PATIENT INJURY OR MEDICAL INTERVENTION ASSOCIATED WITH THIS EVENT. NO ADDITIONAL INFORMATION IS AVAILABLE.
Additional Manufacturer Narrative
CORRECTION TO B5: IT WAS REPORTED THAT A BLOOD/SOLUTION ANAESTHESIA/PCA INFUSION SET WAS FAILING (PREVIOUSLY REPORTED AS A QUANTITY OF 2); THE "SIDE ARM" OF THE SET SPONTANEOUSLY CRACKED MIDWAY THROUGH THE CASE AND STARTED LEAKING ONTO THE FLOOR ADDITIONAL INFORMATION WAS ADDED TO H6. H11: THE ACTUAL DEVICE WAS NOT AVAILABLE; HOWEVER, A PHOTOGRAPH OF THE SAMPLE AND RETENTION SAMPLES WERE PROVIDED FOR EVALUATION. THE RETURNED PHOTOGRAPH WAS REVIEWED, AND IT WAS NOTED THAT THERE WAS A CRACK AT THE LEVEL OF LUER. THE RETENTION SAMPLES WERE VISUALLY INSPECTION AND THERE WERE NO OBVIOUS ISSUE/DAMAGE NOTED. THE RETENTION SAMPLES WERE ALSO LEAK TESTED AND NO ISSUES WERE OBSERVED. THE REPORTED CONDITION WAS VERIFIED IN THE PHOTOGRAPHIC SAMPLE. THE CAUSE OF THE REPORTED CONDITION COULD NOT BE DETERMINED. A BATCH REVIEW WAS CONDUCTED AND THERE WERE NO DEVIATIONS FOUND RELATED TO THIS REPORTED CONDITION DURING THE MANUFACTURE OF THIS LOT. SHOULD ADDITIONAL RELEVANT INFORMATION BECOME AVAILABLE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED.